Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 353-359

  Yamamoto, Tsuyoshi ^a,b   Obika, Satoshi ^a   Nakatani, Moeka ^a,b   Yasuhara, Hidenori ^a,b   Wada, Fumito ^a,b   Shibata, Eiko ^a,b,c   Shibata, Masa Aki ^c   Harada Shiba, Mariko ^b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c OSAKA HEALTH SCIENCE UNIVERSITY   (Japan)

Author keywords

Antisense oligonucleotide; Apolipoprotein C III; Bridged nucleic acids; Hyperlipidemia; Locked nucleic acids; Synthetic nucleic acid

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN C-III; BRIDGED NUCLEIC ACIDS; HYPERLIPIDEMIA; LOCKED NUCLEIC ACIDS; SYNTHETIC NUCLEIC ACID;

ANIMALS; APOLIPOPROTEIN C-III; CHOLESTEROL; KIDNEY; LIPOPROTEINS; LIVER; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84893764655     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.11.004     Document Type: Article

References (44)

1. D. Applebaum-Bowden, J. Kobayashi, V.S. Kashyap, D.R. Brown, A. Berard, S. Meyn, C. Parrott, N. Maeda, R. Shamburek, H.B. Brewer, and S. Santamarina-Fojo Hepatic lipase gene therapy in hepatic lipase-deficient mice - Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium J. Clin. Invest. 97 1996 799 805
2. K. Begriche, J. Massart, M.A. Robin, A. Borgne-Sanchez, and B. Fromenty Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver J. Hepatol. 54 2011 773 794
3. G.A.P. Bruns, S.K. Karathanasis, and J.L. Breslow Human apolipoprotein A-I-C-III gene complex is located on chromosome Arteriosclerosis 4 1984 97 102 (Pubitemid 14152887)
4. S.J. Busch, R.L. Barnhart, G.A. Martin, M.C. Fitzgerald, M.T. Yates, S.J.T. Mao, C.E. Thomas, and R.L. Jackson Human hepatic triglyceride lipase expression reduces high-density-lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice J. Biol. Chem. 269 1994 16376 16382 (Pubitemid 24209337)
5. V. Clavey, S. Lestaveldelattre, C. Copin, J.M. Bard, and J.C. Fruchart Modulation of lipoprotein B binding to the Ldl receptor by exogenous lipids and apolipoprotein-Ci, apolipoprotein-Cii, apolipoprotein-Ciii, and apolipoprotein-E Arterioscl. Throm. Vas. 15 1995 963 971
6. R.M. Crooke, M.J. Graham, K.M. Lemonidis, and K.W. Dobie Modulation of Apolipoprotein C-III Expression 2009 Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals, I. (Ed.)
7. H.L. Dichek, W. Brecht, J.L. Fan, Z.S. Ji, S.P.A. McCormick, H. Akeefe, L. Conzo, D.A. Sanan, K.H. Weisgraber, S.G. Young, J.M. Taylor, and R.W. Mahley Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake J. Biol. Chem. 273 1998 1896 1903 (Pubitemid 28069231)
8. J.L. Fan, J.J. Wang, A. Bensadoun, S.J. Lauer, Q. Dang, R.W. Mahley, and J.M. Taylor Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high-density-lipoproteins and intermediate density lipoproteins Proc. Nat. Acad. Sci. U.S.A. 91 1994 8724 8728 (Pubitemid 24273737)
9. R.M. Fisher, S.W. Coppack, S.M. Humphreys, G.F. Gibbons, and K.N. Frayn Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase Clin. Chim. Acta 236 1995 7 17
10. G. Gerritsen, P.C. Rensen, K.E. Kypreos, V.I. Zannis, L.M. Havekes, and K. Willems van Dijk ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression J. Lipid Res. 46 2005 1466 1473 (Pubitemid 43109811)
11. I.J. Goldberg Clinical review 124 - diabetic dyslipidemia: causes and consequences J. Clin. Endocr. Metab. 86 2001 965 971 (Pubitemid 32322966)
12. M.J. Graham, R.G. Lee, T.A. Bell, W.X. Fu, A.E. Mullick, V.J. Alexander, W. Singleton, N. Viney, R. Geary, J. Su, B.F. Baker, J. Burkey, S.T. Crooke, and R.M. Crooke Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ. Res. 112 2013 (1479-U1221)
13. S.M. Grundy, H.B. Brewer, J.I. Cleeman, S.C. Smith, C. Lenfant, and C. Participants Definition of metabolic syndrome - Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition Circulation 109 2004 433 438 (Pubitemid 38133916)
14. N. Gupta, N. Fisker, M.C. Asselin, M. Lindholm, C. Rosenbohm, H. Orum, J. Elmen, N.G. Seidah, and E.M. Straarup A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo PLoS One 5 2010 e10682
15. R.J. Havel, C.J. Fielding, T Olivecro., V.G. Shore, P.E. Fielding, and T. Egelrud Cofactor activity of protein components of human very low-density lipoproteins in hydrolysis of triglycerides by lipoprotein-lipase from different sources Biochemistry 12 1973 1828 1833
16. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J. Cardiovasc. Risk 3 1996 213 219 (Pubitemid 26266496)
17. R. Holmberg, E. Refai, A. Hoog, R.M. Crooke, M. Graham, G. Olivecrona, P.O. Berggren, and L. Juntti-Berggren Lowering apolipoprotein CIII delays onset of type 1 diabetes Proc. Nat. Acad. Sci. U.S.A. 108 2011 10685 10689
18. Y. Ito, N. Azrolan, A. O'Connell, A. Walsh, and J.L. Breslow Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice Science 249 1990 790 793
19. M.C. Jong, P.C. Rensen, V.E. Dahlmans, H. van der Boom, T.J. van Berkel, and L.M. Havekes Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice J. Lipid Res. 42 2001 1578 1585 (Pubitemid 33026056)
20. 2+ channels exposed to serum from patients with type-I diabetes Science 261 1993 86 90 (Pubitemid 23265382)
21. 2+-dependent beta cell death in type 1 diabetes Proc. Nat. Acad. Sci. U.S.A. 101 2004 10090 10094 (Pubitemid 38891199)
22. P.K.J. Kinnunen, and C. Ehnholm Effect of serum and C-apoproteins from very low-density lipoproteins on human postheparin plasma hepatic lipase FEBS Lett. 65 1976 354 357
23. R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M.E. Munk, S. Kauppinen, and H. Orum Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
24. A.A. Levin A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides Biochim. Biophys. Acta 1489 1999 69 84
25. M.W. Lindholm, J. Elmen, N. Fisker, H.F. Hansen, R. Persson, M.R. Moller, C. Rosenbohm, H. Orum, E.M. Straarup, and T. Koch PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Mol. Ther. 20 2012 376 381
26. J.S. Millar, and C.J. Packard Heterogeneity of apolipoprotein B-100-containing lipoproteins: what we have learnt from kinetic studies Curr. Opin. Lipidol. 9 1998 197 202 (Pubitemid 28274348)
27. D. Milosavljevic, S. Griglio, G. Le Naour, and M.J. Chapman Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages Atherosclerosis 155 2001 251 260 (Pubitemid 32167147)
28. Y. Mitsuoka, T. Kodama, R. Ohnishi, Y. Hari, T. Imanishi, and S. Obika A bridged nucleic acid, 2,4-BNA(COC): synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2,4-BNA(COC) monomers and RNA-selective nucleic-acid recognition Nucleic Acids Res. 37 2009 1225 1238
29. K. Miyashita, S.M.A. Rahman, S. Seki, S. Obika, and T. Imanishi N-Methyl substituted 2 ′,4 ′-BNA(NC): a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization Chem. Commun. 2007 3765 3767 (Pubitemid 47404177)
30. G.D. Norata, C.M. Ballantyne, and A.L. Catapano New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs Eur. Heart J. 34 2013 1783 1789
31. S. Obika, D. Nanbu, Y. Hari, K. Morio, Y. In, T. Ishida, and T. Imanishi Synthesis of 2′-O,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C-3,-endo sugar puckering Tetrahedron Lett. 38 1997 8735 8738 (Pubitemid 27504436)
32. M. Okazaki, S. Usui, M. Ishigami, N. Sakai, T. Nakamura, Y. Matsuzawa, and S. Yamashita Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography Arterioscl. Throm. Vas. 25 2005 578 584 (Pubitemid 40315681)
33. E.M. Ooi, P.H. Barrett, D.C. Chan, and G.F. Watts Apolipoprotein C-III: understanding an emerging cardiovascular risk factor Clin. Sci. (London) 114 2008 611 624 (Pubitemid 351589061)
34. K.F. Petersen, S. Dufour, A. Hariri, C. Nelson-Williams, J.N. Foo, X.M. Zhang, J. Dziura, R.P. Lifton, and G.I. Shulman Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease N. Engl. J. Med. 362 2010 1082 1089
35. T.I. Pollin, C.M. Damcott, H. Shen, S.H. Ott, J. Shelton, R.B. Horenstein, W. Post, J.C. McLenithan, L.F. Bielak, P.A. Peyser, B.D. Mitchell, M. Miller, J.R. O'Connell, and A.R. Shuldiner A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
36. T.P. Prakash, A. Siwkowski, C.R. Allerson, M.T. Migawa, S. Lee, H.J. Gaus, C. Black, P.P. Seth, E.E. Swayze, and B. Bhat Antisense oligonucleotides containing conformationally constrained 2′,4′-(N-methoxy) aminomethylene and 2′,4′-aminooxymethylene and 2′-O,4′- C-aminomethylene bridged nucleoside analogues show improved potency in animal models J. Med. Chem. 53 2010 1636 1650
37. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S.M. Boekholdt, K.T. Khaw, and V. Gudnason Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458 (Pubitemid 46184196)
38. E. Sehayek, and S. Eisenberg Mechanisms of inhibition by apolipoprotein C of apolipoprotein-E-dependent cellular-metabolism of human triglyceride-rich lipoproteins through the low-density-lipoprotein receptor pathway J. Biol. Chem. 266 1991 18259 18267 (Pubitemid 21908074)
39. P.P. Seth, A. Siwkowski, C.R. Allerson, G. Vasquez, S. Lee, T.P. Prakash, E.V. Wancewicz, D. Witchell, and E.E. Swayze Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals J. Med. Chem. 52 2009 10 13
40. T. Takahashi, T. Hirano, K. Okada, and M. Adachi Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice Metabolism 52 2003 1354 1359 (Pubitemid 37351105)
41. S. Usui, Y. Hara, S. Hosaki, and M. Okazaki A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC J. Lipid Res. 43 2002 805 814 (Pubitemid 34477908)
42. C.S. Wang, W.J. McConathy, H.U. Kloer, and P. Alaupovic Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III J. Clin. Invest. 75 1985 384 390 (Pubitemid 15143476)
43. A. Yahara, A.R. Shrestha, T. Yamamoto, Y. Hari, T. Osawa, M. Yamaguchi, M. Nishida, T. Kodama, and S. Obika Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency Chembiochem 13 2012 2513 2516
44. T. Yamamoto, M. Harada-Shiba, M. Nakatani, S. Wada, H. Yasuhara, K. Narukawa, K. Sasaki, M.A. Shibata, H. Torigoe, T. Yamaoka, T. Imanishi, and S. Obika Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice Mol. Ther. Nucleic Acids 1 2012 e22